A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of BIO89-100 Administered Subcutaneously in Subjects With Nonalcoholic Steatohepatitis (NASH) or With Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
Sponsor: 89bio, Inc.
A PHASE1/PHASE2 clinical study on NASH, this trial is completed. The trial is conducted by 89bio, Inc. and has accumulated 11 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Feb 2023 — May 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Feb 2023 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Sep 2021 — Dec 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2019 — Apr 2020 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jul 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- 89bio, Inc.
- ProSciento, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .